Seeking Alpha
Deep value, event-driven, dividend investing, REITs
Profile| Send Message|
( followers)  

As many income investors know, dividend investing can result in the guarantee of income or, in certain cases where the investor has a dividend reinvestment account, more shares. I personally prefer the latter, but that's just me. In the case of the two stocks featured, the dividend increases shouldn't be the only factors taken into account before establishing a position.

Amgen (NASDAQ:AMGN) announced a 31% or $0.11/share increase on December 13, to its current dividend of $0.36/share. It also announced the date of its regular dividend distribution, which is set for March 7th to shareholders of record as of February 13th. As a result of the increase, the company now yields 2.11% ($1.88) on an annual basis, which is then broken down and distributed to shareholders each quarter.

When it comes to Amgen, the dividend hike isn't the only catalyst long-term investors should consider. In fact, there are two ancillary catalysts potential investors need to examine before moving forward. The first catalyst to consider is the fact the stock has surpassed analysts' EPS estimates in each of the last three quarters by an average of 14.23%. The second of the two catalysts to consider is the fact the company also announced a $2 billion stock buyback of which the proceeds would be used to fund future acquisitions.

Investors should note, "Amgen is looking for new products and acquisitions to boost revenue as its former core anemia business declines. The company on Dec. 10 said it had agreed to buy DeCode Genetics Inc., a genetics research company, for $415 million".

CVS Caremark (NYSE:CVS) announced a 38% or $0.06/share increase on December 13, to its current dividend of $0.1625/share. It also announced the date of its regular dividend distribution, which is set for February 4th to shareholders of record as of January 24th. As a result of the increase, the company now yields 1.89% ($0.90) on an annual basis, which is then broken down and distributed to shareholders each quarter.

For potential investors of CVS Caremark, the dividend hike isn't the only catalyst long-term investors should consider. In fact, there are two ancillary catalysts potential investors need to examine before moving forward. The first catalyst to consider is the fact the stock has surpassed analysts' EPS estimates in each of the last three quarters by an average of 1.90%. The second of the two catalysts to consider is the fact the company also announced a better-than-expected outlook for 2013.

In a recent article written by Russ Britt it was noted that CVS Caremark, "sees adjusted earnings next year within a range of $3.84 to $3.98 a share. Analysts polled by FactSet had forecast, on average, earnings of $3.79 a share. The Woonsocket, R.I.-based company added that GAAP earnings should come in at $3.59 to $3.73 a share, while the FactSet estimate had been $3.57 a share". If CVS Caremark can meet or even slightly exceed those numbers, shares could see an additional 3%-4% pop when earnings are announced.

Final Analysis

For potential investors looking to establish a position in either Amgen or CVS Caremark, I'd continue to pay very close attention to the overall state of the U.S. economy, as well as any macro-economic news regarding Obama Care which could have an effect on the overall state of many companies within the Healthcare sector. Based on the streak both companies have established in terms of consecutive dividend payouts, I'd look to initiate a small to medium sized position given their current yields of 2.11% and 1.89%, respectively.

Source: 2 Healthcare Stocks To Consider In The Wake Of 30% Dividend Hikes